Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Site 10
Huntsville, Alabama, United States
Site 8
Huntsville, Alabama, United States
Site 11
Tucson, Arizona, United States
Site 3
Anaheim, California, United States
Site 6
San Francisco, California, United States
Site 15
Stockton, California, United States
Site 26
Melbourne, Florida, United States
Site 22
New Port Richey, Florida, United States
Site 18
Orange City, Florida, United States
Site 27
Pembroke Pines, Florida, United States
Start Date
September 1, 2005
Primary Completion Date
March 1, 2007
Completion Date
March 1, 2007
Last Updated
January 16, 2015
Dronabinol MDI
DRUG
Lead Sponsor
Solvay Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07342296